NAV
$33.42
AUM
$50.2M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| -1.21% | +10.78% | +6.73% | +33.73% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 18.17% |
| 2 | NVO | Novo Nordisk AS ADR | 13.13% |
| 3 | PFE | Pfizer Inc | 6.40% |
| 4 | VKTX | Viking Therapeutics Inc | 4.80% |
| 5 | 1093.HK | CSPC Pharmaceutical Group Ltd | 4.50% |
| 6 | KLRA | Kailera Therapeutics Inc | 4.44% |
| 7 | 4519.T | Chugai Pharmaceutical Co Ltd | 4.28% |
| 8 | ZEAL.CO | Zealand Pharma AS | 4.14% |
| 9 | 128940.KS | Hanmi Pharm Co Ltd | 4.01% |
| 10 | 1801.HK | Innovent Biologics Inc | 4.00% |
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
Inception Date: 2024-05-20